Eli Lilly Japan K.K., Kobe, Japan.
J Dermatolog Treat. 2023 Dec;34(1):2229465. doi: 10.1080/09546634.2023.2229465.
Real-world evidence on persistence of interleukin-17 inhibitors (IL-17i) as a drug class among Japanese patients with psoriasis is lacking. Hence, we aimed to describe persistence rates of IL-17is among patients with psoriasis including psoriasis vulgaris (PsO), psoriatic arthritis (PsA), and generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP) in Japan.
We analyzed claims data from the Medical Data Vision database. Patients ≥15 years old with a psoriasis diagnosis and an IL-17i prescription between November 2016 and August 2020 were included and followed through August 2021. Persistence rates of the IL-17i class among patients with psoriasis and its subtypes (PsO, PsA, and GPP or EP), and persistence rates of ixekizumab, secukinumab, or brodalumab among patients with PsO or PsA were analyzed using Kaplan-Meier method. Analyses were conducted in the bio-naïve and bio-experienced subgroups.
The IL-17i class had >50% persistence rates up to 36 months among patients with psoriasis and its subtypes (PsO, PsA, and GPP or EP). 36-Month persistence rates for ixekizumab, secukinumab, and brodalumab were 46.2% to 57.7% in patients with PsO and 43.0% to 48.4% in patients with PsA. Across analyses, bio-naïve patients demonstrated similar or greater persistence rates than bio-experienced patients.
IL-17is' persistence rates over 36 months were >50% among patients with psoriasis and its subtypes (PsO, PsA, and GPP or EP) in Japan.
关于白介素-17 抑制剂（IL-17i）作为一类药物在日本银屑病患者中的持续性，目前缺乏真实世界的数据。因此，我们旨在描述日本银屑病患者（包括寻常型银屑病[PsO]、银屑病关节炎[PsA]、泛发性脓疱型银屑病[GPP]或红皮病型银屑病[EP]）中 IL-17i 的持续性。
我们分析了来自 Medical Data Vision 数据库的索赔数据。纳入了年龄≥15 岁、在 2016 年 11 月至 2020 年 8 月间有银屑病诊断和 IL-17i 处方、并随访至 2021 年 8 月的患者。使用 Kaplan-Meier 法分析了银屑病及其亚型（PsO、PsA 和 GPP 或 EP）患者中 IL-17i 类药物的持续性，以及 PsO 或 PsA 患者中依奇珠单抗、司库奇尤单抗或布罗达单抗的持续性。分析在生物初治和生物经验丰富亚组中进行。
银屑病及其亚型（PsO、PsA 和 GPP 或 EP）患者中，IL-17i 类药物在 36 个月时的持续性率＞50%。在 PsO 患者中，依奇珠单抗、司库奇尤单抗和布罗达单抗的 36 个月持续性率为 46.2%至 57.7%，在 PsA 患者中为 43.0%至 48.4%。在所有分析中，生物初治患者的持续性率与生物经验丰富患者相似或更高。
在日本，银屑病及其亚型（PsO、PsA 和 GPP 或 EP）患者中，IL-17i 的 36 个月持续性率＞50%。
